Page last updated: 2024-11-01

ondansetron and Cardiac Diseases

ondansetron has been researched along with Cardiac Diseases in 2 studies

Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gallegos-Castorena, S1
Martínez-Avalos, A1
Mohar-Betancourt, A1
Guerrero-Avendaño, G1
Zapata-Tarrés, M1
Medina-Sansón, A1
Kosmidis, PA1
Kalofonos, HP1
Christodoulou, C1
Syrigos, K1
Makatsoris, T1
Skarlos, D1
Bakogiannis, C1
Nicolaides, C1
Bafaloukos, D1
Bamias, A1
Samantas, E1
Xiros, N1
Boukovinas, I1
Fountzilas, G1
Dimopoulos, MA1

Trials

2 trials available for ondansetron and Cardiac Diseases

ArticleYear
Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin.
    Pediatric hematology and oncology, 2007, Volume: 24, Issue:6

    Topics: Adolescent; Amifostine; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms;

2007
Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino

2008